Serotyping and genotyping of hepatitis C virus (HCV) strains in chronic HCV infection. Commission Hepatologie du CREGG. Club de Reflexion des Cabinets de Groupes en GastroEnterologie.
Hepatitis C virus (HCV) genotypes can be established by methods based on PCR typing and serological typing. The accuracy of these methods depends on their sensitivity and specificity. These should be compared with the reference method, direct sequencing, and analysis of viral genomes. Among the serologic methods recently developed, the performance of a new serotyping assay (RIBA HCV 3.0 SIA, Chiron corporation, Emeryville) was assessed using a panel of 147 well-characterized French isolates from chronic hepatitis C patients. Definitive genotypes of the isolates were established by direct sequencing in 5' NC and in some cases in NS-5B. HCV serotypes 1, 2, and 3 were determined by measuring type specific antibodies to core and NS-4 derived peptide antigens. Of the 147 sera, serotypic-specific antibodies were detected in 136 (sensitivity, 92.5%). The specificity of the RIBA SIA HCV serotyping assay was 92.6% (including samples with mixed results); without these, the specificity was 80.1%. Analysis of the 28 discrepant samples showed that (1) a different serotype was found in 18 samples including five for genotype 1, three for genotype 2, two for genotype 3, five for genotype 4, and three for genotype 5, and that (2) ten patients showed a reactivity with mixed serotypes, one had circulating antibodies to type 1 or 2, and nine had circulating antibodies to type 1 or 3. In summary, except for genotypes 4 and 5, the results of the test were well correlated (85.7%) with those of direct sequence genotyping. The former test is rapid and does not require the strict HCV RNA storage and preservation conditions of the latter. This new method may thus be considered as an alternative for HCV typing. However, although it is convenient, its lower sensitivity compared to the molecular typing method and the discrepant results limit its routine use in a clinical context.
Halfon
P
P
Laboratoire Alphabio, Marseille, France.
Ouzan
D
D
Khiri
H
H
Feryn
J M
JM
D000914:Antibodies, Viral / Q000097:blood; D005069:Evaluation Studies as Topic; D005260:Female; D005602:France; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics* / Q000276:immunology; D006526:Hepatitis C / Q000276:immunology / Q000821:virology*; D006521:Hepatitis, Chronic / Q000276:immunology / Q000821:virology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000706:statistics & numerical data; D008297:Male; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012680:Sensitivity and Specificity; D012703:Serotyping / Q000379:methods* / Q000706:statistics & numerical data; D014773:Virology / Q000379:methods / Q000706:statistics & numerical data
D000914:Antibodies, Viral; D012367:RNA, Viral